IL-1β RECEPTOR ANTAGONIST PEPTIDE ASSOCIATED WITH PHOTOBIOMODULATION PROMOTES HEALING OF DIABETIC WOUNDS

Diabetes mellitus (DM) is characterized by a severe metabolic disorder that has long-term systemic repercussions. Chronic hyperglycemia slows down the healing process due to prolonged inflammation that impedes the progression of regeneration. One of the characteristics of the diabetic wound is the high levels of IL-1β, which increases the expression of adhesion molecules in the endothelium and perpetuates the inflammatory process. Photobiomodulation (PBM) is considered a non-pharmacological intervention that consists of the application of a form of non-ionized light, which includes low-power laser, with anti-inflammatory and biostimulatory effects that accelerate the healing process. The association of PBM with the development of a peptide that attenuates IL-1β responses represents a promising option for the treatment of epithelial lesions; since its excess leads to senescence of fibroblasts, reduction of growth factors and degradation of ECM proteins.